Kell metallo-endopeptidase (KEL)

Kell metallo-endopeptidase is a highly polymorphic, type II transmembrane glycoprotein primarily expressed on erythrocytes as the Kell blood group antigen. The protein is covalently bound to XK (Kx antigen) forming the Kell blood group system, which comprises over 25 antigenic variants. Kell functions as a zinc-dependent endopeptidase, specifically converting the precursor big endothelin-3 into the active vasoconstrictor peptide endothelin-3, implicating it in vascular regulation. Its expression and alloantigenicity make Kell a key target in transfusion medicine, as anti-Kell antibodies may trigger severe hemolytic reactions and hemolytic disease of the fetus/newborn. Genetic alterations affecting Kell or XK have important pathological consequences, including the neuroacanthocytosis syndrome McLeod. Kell belongs to the neprilysin (M13) family and may have evolutionary significance in host immune and vascular regulatory mechanisms.

Other names

Kell blood group glycoproteinCD238ECE3 (Endothelin-converting enzyme 3)Kell glycoproteinKell blood group antigenKell blood group proteinBlood group Kell proteinMetallo-endopeptidase, KellKELLKx antigen (Kx is the associated XK protein, often mentioned together in context)

Antibody-mediated clearance: Alloantibodies bind Kell antigens, leading to destruction/removal of RBCs (the primary pathogenesis in hemolytic reactions) Inhibition of enzymatic activity: Hypothetically, inhibitors could block endothelin-3 conversion, affecting vasoactivity, though not clinically implemented Diagnostic use: Antibody detection for transfusion compatibility and disease risk stratification